Navigation Links
Life Technologies Makes Automated Cell Imaging Accessible to All Labs
Date:7/15/2013

CARLSBAD, Calif., July 15, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announces the launch of EVOS® FL Auto Imaging System with an on-stage incubator designed to enable time-lapse, high-resolution live cell imaging in a fully automated system that is priced to make high-resolution, fluorescence microscopy simple and accessible for any lab.

Priced significantly less than other instruments on the market, the EVOS® FL Auto Imaging System is a fully integrated platform capable of meeting a broad range of research applications, from image tiling and multi-position well scanning to automated cell counting. When combined with the incubator system, which controls environmental temperature, oxygen and humidity directly on the instrument stage, the cell imaging system enables longer live cell culture monitoring sessions and time-lapse imaging.

"When I was a post doc, people spent more than a year getting a confocal system with live cell chamber to work," said Karen Schindler, assistant professor, Rutgers University, Department of Genetics. "When I started my lab, I looked for a system that was easy to use, had a small footprint and could support our finicky cells. I was skeptical to have the demo on the EVOS system done in two days.  It was so easy. I realized even students with limited knowledge could use it."

Simple and Economical to Use

At the heart of the system is its intuitive and automated workflow, which underscores Life Technologies' commitment to developing innovative platforms that benefit its customers and support their cell analysis research. The EVOS® FL Auto Imaging System is designed for novice and experienced users alike with minimal upfront training requirements. The system's proprietary EVOS® LED light cubes also reduce operational costs, eliminating the need to replace burned-out arc lamps.  

"The EVOS FL Auto Imaging System provides an excellent value giving researchers a full-featured, multichannel fluorescent instrument that does not require an in-lab expert to operate," said Siddhartha Kadia, Ph.D., President, Life Sciences at Life Technologies. "It represents our drive to provide the industry with innovative microscopy platforms that reduce complexity and allow our customers to spend less time on instrument operation and more time analyzing results."

The EVOS® FL Auto Imaging System is for research use only, not intended for diagnostic purposes.

About Life Technologies 

Life Technologies Corporation (NASDAQ:  LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Mauricio Minotta
760-929-2456
Mauricio.minotta@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Antiviral Therapeutics Report - Technologies, Markets and Companies - 2013-2022
2. Membrane Microfiltration Market and Membrane Separation Technologies Research Reports
3. Cynosure Completes Acquisition of Palomar Medical Technologies
4. Breast Imaging Technologies Market - Technology and Market Analysis & Global Forecasts to 2017
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Dynavax Technologies Corporation To Contact The Firm
6. Drug Delivery Technologies Market Report - Global Forecasts To 2017
7. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
8. MicroTechnologies Announces Award of Medical Device Contract Manufacturing Line
9. Life Technologies Expands Range of Stem Cell Reprogramming Solutions
10. Drug Delivery in Cancer - Technologies, Markets and Companies 2013
11. Life Technologies Acquires LSK, Leading Instruments Distributor in Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , April 24, 2017 Solentim, ... today announced the addition of a major new ... In-situ Plate Seeding,). The VIPS has been developed ... 384 well microplates as part of the process ... offers a simple and more reliable solution when ...
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
Breaking Medicine News(10 mins):